Canterbury DHB


Prognosis and Management of CEL-NOS

Patients rarely respond to imatinib or interferon α.

Prognosis is variable, but generally thought to be poor, and transformation to acute leukemia is common. One small series6 gave median survival of 22.2 months.

Adverse risk factors include:

About this Canterbury DHB document (537415):

Document Owner:

Bridgett McDiarmid (see Who's Who)

Last Reviewed:

August 2018

Next Review:

April 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 537415